The Role of Systolic Blood Pressure Reduction in Diastolic Dysfunction: RAAS Inhibition versus Non-RAAS Blood Pressure Lowering.
作者信息
Park Sung Ji
机构信息
Division of Cardiology, Department of Medicine, Cardiovascular Imaging Center, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
出版信息
J Cardiovasc Imaging. 2020 Jul;28(3):183-185. doi: 10.4250/jcvi.2020.0083.
Abstract
摘要
相似文献
1
The Role of Systolic Blood Pressure Reduction in Diastolic Dysfunction: RAAS Inhibition versus Non-RAAS Blood Pressure Lowering.收缩压降低在舒张功能障碍中的作用：肾素-血管紧张素-醛固酮系统（RAAS）抑制与非RAAS降压治疗
J Cardiovasc Imaging. 2020 Jul;28(3):183-185. doi: 10.4250/jcvi.2020.0083.
2
The effect of valsartan versus non-RAAS treatment on autoregulation of cerebral blood flow.缬沙坦与非 RAAS 治疗对脑血流自动调节的影响。
Cerebrovasc Dis. 2012;34(1):78-85. doi: 10.1159/000338777. Epub 2012 Jul 14.
3
RAAS polymorphisms alter the acute blood pressure response to aerobic exercise among men with hypertension.肾素-血管紧张素-醛固酮系统（RAAS）基因多态性改变高血压男性对有氧运动的急性血压反应。
Eur J Appl Physiol. 2006 May;97(1):26-33. doi: 10.1007/s00421-006-0142-8. Epub 2006 Feb 9.
4
Blood Pressure Lowering and Safety Improvements With Liver Angiotensinogen Inhibition in Models of Hypertension and Kidney Injury.肝血管紧张素原抑制在高血压和肾损伤模型中降低血压和提高安全性。
Hypertension. 2017 Sep;70(3):566-576. doi: 10.1161/HYPERTENSIONAHA.117.09755. Epub 2017 Jul 17.
5
Fibroblast growth factor 23 and the antiproteinuric response to dietary sodium restriction during renin-angiotensin-aldosterone system blockade.成纤维细胞生长因子 23 与肾素-血管紧张素-醛固酮系统阻断期间饮食钠限制的抗蛋白尿反应。
Am J Kidney Dis. 2015 Feb;65(2):259-66. doi: 10.1053/j.ajkd.2014.07.022. Epub 2014 Sep 30.
6
Role of the renin-angiotensin-aldosterone system and inflammatory processes in the development and progression of diastolic dysfunction.肾素-血管紧张素-醛固酮系统及炎症过程在舒张功能障碍发生发展中的作用
Clin Sci (Lond). 2009 Mar;116(6):467-77. doi: 10.1042/CS20080390.
7
Blood Pressure Lowering and Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2is): More Than Osmotic Diuresis.降压与钠-葡萄糖共转运蛋白 2 抑制剂（SGLT2is）：不仅仅是渗透性利尿。
Curr Hypertens Rep. 2019 Feb 12;21(2):12. doi: 10.1007/s11906-019-0920-4.
8
Effect of intensive versus standard blood pressure lowering on diastolic function in patients with uncontrolled hypertension and diastolic dysfunction.强化降压与标准降压对未控制高血压伴舒张功能障碍患者舒张功能的影响。
Hypertension. 2010 Feb;55(2):241-8. doi: 10.1161/HYPERTENSIONAHA.109.138529. Epub 2009 Dec 7.
9
Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.肾素-血管紧张素-醛固酮系统的抑制作用：聚焦于阿利吉仑。
J Assoc Physicians India. 2010 Feb;58:102-8.
10
Clinical trial of arotinolol in the treatment of hypertension: dippers vs. non-dippers.阿罗洛尔治疗高血压的临床试验：杓型血压者与非杓型血压者
Hypertens Res. 2001 Sep;24(5):605-10. doi: 10.1291/hypres.24.605.
本文引用的文献
1
Addition of Amlodipine or Valsartan for Improvement of Diastolic Dysfunction Associated with Hypertension.加用氨氯地平或缬沙坦改善高血压相关的舒张功能障碍。
J Cardiovasc Imaging. 2020 Jul;28(3):174-182. doi: 10.4250/jcvi.2020.0005. Epub 2020 May 27.
2
Diastolic Dysfunction and Hypertension.舒张功能障碍与高血压。
Med Clin North Am. 2017 Jan;101(1):7-17. doi: 10.1016/j.mcna.2016.08.013.
3
Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.超声心动图评估左心室舒张功能的建议：美国超声心动图学会和欧洲心血管影像学会的更新
Eur Heart J Cardiovasc Imaging. 2016 Dec;17(12):1321-1360. doi: 10.1093/ehjci/jew082. Epub 2016 Jul 15.
4
Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap.射血分数保留的心力衰竭的表型特异性治疗：多器官路线图
Circulation. 2016 Jul 5;134(1):73-90. doi: 10.1161/CIRCULATIONAHA.116.021884.
5
Pre-clinical diastolic dysfunction.临床前舒张功能障碍。
J Am Coll Cardiol. 2014 Feb 11;63(5):407-16. doi: 10.1016/j.jacc.2013.10.063. Epub 2013 Nov 27.
6
Prognostic significance of left ventricular diastolic dysfunction in patients with left ventricular hypertrophy and systemic hypertension (the LIFE Study).左心室肥厚伴系统性高血压患者左心室舒张功能障碍的预后意义（LIFE 研究）。
Am J Cardiol. 2010 Oct 1;106(7):999-1005. doi: 10.1016/j.amjcard.2010.05.032.
7
Differential effects of antihypertensive treatment on left ventricular diastolic function: an ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) substudy.降压治疗对左心室舒张功能的差异影响：ASCOT（盎格鲁-斯堪的纳维亚心脏结局试验）子研究。
J Am Coll Cardiol. 2010 Apr 27;55(17):1875-81. doi: 10.1016/j.jacc.2009.11.084.
8
Effect of intensive versus standard blood pressure lowering on diastolic function in patients with uncontrolled hypertension and diastolic dysfunction.强化降压与标准降压对未控制高血压伴舒张功能障碍患者舒张功能的影响。
Hypertension. 2010 Feb;55(2):241-8. doi: 10.1161/HYPERTENSIONAHA.109.138529. Epub 2009 Dec 7.
9
Diastolic dysfunction as a link between hypertension and heart failure.舒张功能障碍作为高血压与心力衰竭之间的联系。
Med Clin North Am. 2009 May;93(3):647-64. doi: 10.1016/j.mcna.2009.02.013.
10
Tissue velocity echocardiography shows early improvement in diastolic function with irbesartan and atenolol therapy in patients with hypertensive left ventricular hypertrophy. Results form the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA).组织速度超声心动图显示，在高血压左心室肥厚患者中，厄贝沙坦和阿替洛尔治疗可使舒张功能早期改善。瑞典厄贝沙坦与阿替洛尔治疗左心室肥厚研究（SILVHIA）的结果。
Am J Hypertens. 2006 Sep;19(9):927-36. doi: 10.1016/j.amjhyper.2006.02.009.
Zotero 插件